newsfilter
← Latest News
PR Newswire·

RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259

ROCKVILLE, Md., June 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today that its U.S. joi